Cargando…
Modelling and simulation as research tools in paediatric drug development
PURPOSE: Although practical and ethical constraints impose special requirements for the evaluation of treatment safety and efficacy in children, the main issue remains the empirical basis for patient stratification and dose selection at the early stage of the development of new chemical and biologic...
Autores principales: | Bellanti, Francesco, Della Pasqua, Oscar |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082698/ https://www.ncbi.nlm.nih.gov/pubmed/21246352 http://dx.doi.org/10.1007/s00228-010-0974-3 |
Ejemplares similares
-
Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
por: Bellanti, Francesco, et al.
Publicado: (2011) -
Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients
por: Romano, Federico, et al.
Publicado: (2021) -
Modeling and Simulation as a Tool to Bridge Efficacy and Safety Data in Special Populations
por: Harnisch, L, et al.
Publicado: (2013) -
PBPK modeling and simulation in drug research and
development
por: Zhuang, Xiaomei, et al.
Publicado: (2016) -
Model-Based Optimisation of Deferoxamine Chelation Therapy
por: Bellanti, Francesco, et al.
Publicado: (2015)